GlassScriptPhysician profile
Nathaniel Thomas Jablecki
NPI 1598979312
$1,418.16
in general payments reported to CMS, 2019-2025
27 companies · $34.43 in 2025
The $34.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.77 · 2020: $337 · 2021: $118 · 2022: $537 · 2023: $352 · 2024: $27.62 · 2025: $34.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $231.20 | 2020-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $220.88 | 2020-2023 | |
| Abbott Laboratories | $137.00 | 2022-2023 | Freestyle Libre 3 |
| Amgen INC. | $122.42 | 2021-2024 | Repatha, Otezla |
| Lilly USA, LLC | $106.65 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.96 | 2020-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $54.72 | 2022 | |
| Glaxosmithkline, LLC. | $47.93 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $43.88 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $41.83 | 2020 | |
| Pfizer INC. | $37.13 | 2022-2023 | |
| Nevro Corp. | $36.47 | 2023 | Senza |
| Eisai INC. | $34.39 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $22.11 | 2022 | |
| Ibsa Pharma INC. | $19.96 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $19.61 | 2022 | |
| Astellas Pharma US INC | $18.34 | 2020 | |
| Ironwood Pharmaceuticals, INC | $18.06 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.78 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.57 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.85 | 2020 | |
| Exact Sciences Corporation | $13.51 | 2024 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $12.90 | 2021 | |
| Aytu Biopharma, INC. | $12.90 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.82 | 2020 | |
| Allergan, INC. | $11.77 | 2019 | |
| Orthofix Medical, INC. | $4.52 | 2025 | Physio-Stim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Jablecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.